Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID11844898. S2CID72629130.
Austin SM, el-Hayek A, Comianos M, Tamulonis DJ (October 1993). "Mitral valve disease associated with long-term ergotamine use". Southern Medical Journal. 86 (10): 1179–1181. doi:10.1097/00007611-199310000-00024. PMID8211344.
nih.gov
pubmed.ncbi.nlm.nih.gov
Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID11844898. S2CID72629130.
Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID11844898. S2CID72629130.